Bipolar Disorder (Manic Depression) Pipeline Insights 2019 - Developmental Stage, Associated Indications, Route of Administration and Molecule Type - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 25, 2019--The “Bipolar Disorder (Manic Depression) - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Bipolar Disorder (Manic Depression) - Pipeline Insight, 2019 report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Bipolar Disorder (Manic Depression) development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:Clinical Non-clinical Inactive: Discontinued and/or Dormant
Descriptive coverage of pipeline development activities for Bipolar Disorder (Manic Depression)
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Pipeline Therapeutics assessment of products for Bipolar Disorder (Manic Depression)
The report assesses the active Bipolar Disorder (Manic Depression) pipeline products by developmental stage, product type, molecule type, and administration route.
Companies MentionedAequus Pharmaceuticals Inc. Amorsa Therapeutics Inc. AstraZeneca Plc Biogen Inc Delpor Inc. Intas Pharmaceuticals Ltd. Intra-Cellular Therapies Inc. Johnson & Johnson KemPharm Inc. Mapi Pharma Ltd. Navya Biologicals Pvt Ltd Neurocrine Biosciences Inc Omeros Corporation Otsuka Holdings Co. Ltd.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/chgc2g/bipolar_disorder?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190125005404/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Mental Health,Mental Disorders Drugs
INDUSTRY KEYWORD: HEALTH MENTAL HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 01/25/2019 12:56 PM/DISC: 01/25/2019 12:56 PM